VRNA

Verona Pharma Plc - ADR

$4.48

chg

-0.12 (-2.61%)

quotes and stock data may be delayed 15 minutes

52 wk low

4.37

52 wk hi

9.72

Cash

$166.5 M

Burn Rate (Qtr)

$11.1 M

Mkt Cap

$269.0m

Avg Volume

37,161

*cash/burn updated:

Q3 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Ensifentrine (Nebulized) (PDE3 and PDE4 inhibitor)

Chronic obstructive pulmonary disease

Phase 3

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Ensifentrine (Inhaled) (PDE3 and PDE4 inhibitor)

Chronic obstructive pulmonary disease

Phase 3

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Ensifentrine (Nebulized) (PDE3 and PDE4 inhibitor)

Lung disease, Asthma

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Ensifentrine (Nebulized) (PDE3 and PDE4 inhibitor)

Cystic fibrosis

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Ensifentrine (Inhaled) (PDE3 and PDE4 inhibitor)

COVID-19

Failed

Discontinued

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

VRNA

BPIQ_Logo_RGB-01.jpg

Company Profile

Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. We are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (COPD) and cystic fibrosis (CF), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases.

We are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. In addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation.

Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA and on the London Stock Exchange in the United Kingdom under the ticker symbol VRP.L. We are headquartered in London and have offices in the United States.

Recent Posts

See what the community is saying - click to see full post.